Arca
Skip to content
Tools
Tools

Label Changes: Welireg (belzutifan)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Welireg label DailyMed has published, from Merck Sharp & Dohme LLC, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 9
  • Sections changed, version 12 to 13: 12, Including the boxed warning

What changed from version 12 to version 13

Jun 29, 2026 to Oct 12, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Boxed warningChanged · 1 word added, 1 removed
  2. Indications and usageChanged · 45 words added, 14 removed
  3. Dosage and administrationChanged · 121 words added, 3 removed
  4. Warnings and precautionsChanged · 320 words added, 2 removed
  5. Adverse reactionsChanged · 835 words added, 18 removed
  6. Use in specific populationsChanged · 293 words added, 88 removed
  7. Clinical pharmacologyChanged · punctuation or symbols only
  8. Nonclinical toxicologyChanged · 58 words added, 8 removed
  9. Clinical studiesChanged · 604 words added, 12 removed
  10. Patient counseling informationChanged · 131 words added, 1 removed
  11. Medication guideChanged · 309 words added, 48 removed
  12. Untitled sectionChanged · 1 word added, 2 removed

Boxed warning

Changed1 word added, 1 removed
2 unchanged lines
Verify pregnancy status prior to the initiation of WELIREG.
Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective [see Warnings and Precautions (5.34), Drug Interactions (7.2), Use in Specific Populations (8.1, 8.3)].

Indications and usage

Changed45 words added, 14 removed
1 INDICATIONS AND USAGE
1.1 von Hippel-Lindau (VHL) disease
WELIREG is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
1.2 Renal Cell Carcinoma with a Clear Cell Component (ccRCC)
WELIREG, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the adjuvant treatment of adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
WELIREG, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
WELIREG, as monotherapy, is indicated for the treatment of adult patients with advanced ccRCC following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
1.3 Pheochromocytoma or Paraganglioma (PPGL)
WELIREG is indicated for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).

Dosage and administration

Changed121 words added, 3 removed
6 unchanged lines
Adjuvant Treatment of ccRCC | 120 mg orally once daily in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph. | Until disease recurrence or unacceptable toxicity, or up to 54 weeks.
Treatment of Advanced ccRCC | 120 mg orally once daily as monotherapy or in combination with lenvatinib. | Until disease progression or unacceptable toxicity.
Pheochromocytoma or Paraganglioma | Adults: 120 mg orally once daily. Pediatric patients 12 years and older based on bodyweight: Patients weighing 40 kg or greater: 120 mg orally once daily. Patients weighing less than 40 kg: 80 mg orally once daily. | Until disease progression or unacceptable toxicity.
Administration Instructions
WELIREG should be taken at the same time each day and may be taken with or without food [see Clinical Pharmacology (12.3)].
Advise patients to swallow tablets whole. Do not chew, crush, or split WELIREG prior to swallowing.
2 unchanged lines
2.2 Dosage Modifications for Adverse Reactions
Dosage modifications for WELIREG for adverse reactions are summarized in Table 2 and Table 3.
The recommended dose reductions are:
5 unchanged lines
Anemia [see Warnings and Precautions (5.1)] | Adjuvant ccRCC Indication:
| Hemoglobin <9 g/dL or transfusion indicated | Withhold WELIREG until hemoglobin ≥9 g/dL. Resume WELIREG at the same or reduced dose; or discontinue depending on the severity of anemia.
| Life-threatening or urgent intervention indicated | Withhold WELIREG until hemoglobin ≥9 g/dL. Resume WELIREG at a reduced dose once resolved, or permanently discontinue.
| All Other Indications:
| Hemoglobin <8 g/dL or transfusion indicated | Withhold WELIREG until hemoglobin ≥8 g/dL. Resume WELIREG at the same or reduced dose; or discontinue depending on the severity of anemia.
| Life-threatening or urgent intervention indicated | Withhold WELIREG until hemoglobin ≥8g8 g/dL. Resume WELIREG at a reduced dose once resolved, or permanently discontinue.
Hypoxia [see Warnings and Precautions (5.2)] | Decreased oxygen saturation with exercise (e.g., pulse oximeter <88%) | Consider withholding WELIREG until resolved. Resume WELIREG at the same dose or at a reduced dose depending on the severity of hypoxia.
3 unchanged lines
Refer to the Prescribing Information of the individual therapeutic agents used in combination with WELIREG for dosage modifications for adverse reactions.
Additional recommended dosage modifications for adverse reactions when WELIREG is administered in combination with lenvatinib are provided in Table 3.
Table 3: Recommended Dosage Modifications for Adverse Reactions for WELIREG in Combination with Lenvatinib
Adverse Reaction | Severity | Dosage Modification
Cardiac Dysfunction [see Warnings and Precautions (5.3)] | Grade 3 | Withhold both WELIREG and lenvatinib until LVEF improves to baseline or Grade 1. Resume WELIREG and lenvatinib at a reduced dose or permanently discontinue depending on the severity and persistence of adverse reaction.
Grade 4 | Permanently discontinue both WELIREG and lenvatinib.
Refer to the Prescribing Information of lenvatinib for additional dosage modifications for adverse reactions.

Warnings and precautions

Changed320 words added, 2 removed
8 unchanged lines
In LITESPARK-005, decreased hemoglobin occurred in 88% of patients and 29% had Grade 3 events [see Adverse Reactions (6.1)]. Median time to onset of anemia was 29 days (range: 1 day to 16.6 months). Of the patients with anemia, 22% received transfusions only, 20% of patients received ESAs only and 12% received both transfusion and ESAs.
In LITESPARK-022, decreased hemoglobin occurred in 95% of patients receiving WELIREG in combination with pembrolizumab and 11% had Grade 3 or higher events [see Adverse Reactions (6.1)]. Median time to onset of anemia was 42 days (range: 1 day to 11.1 months). Of the patients with anemia, 5% received transfusions only, 8% received ESAs only, and 1.3% received both transfusion and ESAs.
In LITESPARK-011, decreased hemoglobin occurred in 87% of patients receiving WELIREG in combination with lenvatinib and 20% had Grade 3 events or required transfusion [see Adverse Reactions (6.1)]. Median time to onset of anemia was 56 days (range: 1 day to 33 months). Of the patients with anemia, 15% of patients received transfusions only, 22% received ESAs only, and 8% received both transfusion and ESAs.
Pheochromocytoma or Paraganglioma (PPGL)
8 unchanged lines
In LITESPARK-005, hypoxia occurred in 15% of patients and 10% had Grade 3 events [see Adverse Reactions (6.1)]. Of the patients with hypoxia, 69% were treated with oxygen therapy. Median time to onset of hypoxia was 30.5 days (range: 1 day to 21.1 months).
In LITESPARK-022, hypoxia occurred in 7% of patients receiving WELIREG in combination with pembrolizumab and 5% had Grade 3 or higher events [see Adverse Reactions (6.1)]. Of the patients with hypoxia, 47% were treated with oxygen therapy. Median time to onset of hypoxia was 93 days (range: 9 days to 11.7 months).
In LITESPARK-011, hypoxia occurred in 16% of patients receiving WELIREG in combination with lenvatinib 12% had Grade 3-4 events [see Adverse Reactions (6.1)]. Of the patients with hypoxia, 62% of patients were treated with oxygen therapy. Median time to onset was 63 days (range: 4 days to 25 months).
Pheochromocytoma or Paraganglioma (PPGL)
In LITESPARK-015, hypoxia occurred in 13% of patients and 10% had Grade 3 hypoxia [see Adverse Reactions (6.1)]. Median time to onset of hypoxia was 35 days (range: 6 days to 23.9 months). Of the patients with hypoxia, 67% were treated with oxygen therapy.
5.3 Cardiac Dysfunction with Concomitant Use of WELIREG and Lenvatinib
Serious cardiac dysfunction, including heart failure with reduced left ventricular ejection fraction (LVEF), and cardiomyopathy, can occur with WELIREG in combination with lenvatinib. The safety of WELIREG in combination with lenvatinib has not been established in patients with LVEF below 50%.
In patients treated with WELIREG in combination with lenvatinib in the LITESPARK-011 trial, Grade 3 or higher cardiac dysfunction adverse events occurred in 6% of patients. The median time to onset of Grade 3 or higher cardiac dysfunction was 26 weeks (range: 1 to 192 weeks). An absolute decrease in LVEF >20% with or without clinical symptoms occurred in 6% of patients. The median time to onset of LVEF decrease >20% was 29 weeks (range: 2 to 192 weeks).
Consider obtaining a baseline echocardiogram or Multigated Acquisition (MUGA) imaging. Monitor patients for symptoms or signs of heart failure and if present, reassess LVEF. Withhold and resume at a reduced dose upon recovery to baseline or Grade 1 or permanently discontinue WELIREG in combination with lenvatinib based on severity [see Dosage and Administration (2.2)].
5.34 Embryo-Fetal Toxicity
Based on findings in animals, WELIREG can cause fetal harm when administered to a pregnant woman. In an animal reproduction study, oral administration of belzutifan to pregnant rats during the period of organogenesis caused embryo-fetal lethality, reduced fetal body weight, and fetal skeletal malformations at maternal exposures ≥0.2 times the human exposures (AUC) at the recommended dose of 120 mg daily.
Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with WELIREG and for 1 week after the last dose, since WELIREG can render some hormonal contraceptives ineffective [see Drug Interactions (7.12)]. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with WELIREG and for 1 week after the last dose [see Use in Specific Populations (8.1, 8.3)].

Adverse reactions

Changed835 words added, 18 removed
3 unchanged lines
Hypoxia [see Warnings and Precautions (5.2)]
Cardiac Dysfunction with Concomitant Use of WELIREG and Lenvatinib [see Warnings and Precautions (5.3)]
6.1 Clinical Trials Experience
8 unchanged lines
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG were decreased hemoglobin, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.
Table 34 summarizes the adverse reactions reported in patients treated with WELIREG in LITESPARK-004.
Table 34: Adverse Reactions Occurring in ≥10% of Patients Who Received WELIREG in LITESPARK-004
Adverse Reaction | WELIREG (n=61)
22 unchanged lines
Weight increased | 12 | 1.6
Table 45 summarizes the laboratory abnormalities in LITESPARK-004.
Table 45: Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received WELIREG in LITESPARK-004
Laboratory Abnormality | WELIREG (n=61)
12 unchanged lines
LITESPARK-022
The safety of WELIREG in combination with intravenous pembrolizumab versus placebo in combination with intravenous pembrolizumab was investigated in LITESPARK-022, a randomized, double-blind trial in 1,828 patients who had undergone nephrectomy for ccRCC [see Clinical Studies (14.2)]. Patients received either WELIREG 120 mg orally once daily in combination with pembrolizumab 400 mg intravenously every 6 weeks (n=915), or oral placebo in combination with pembrolizumab 400 mg intravenously every 6 weeks (n=913) for up to 9 cycles (54 weeks) until disease recurrence or unacceptable toxicity. The median duration of exposure to WELIREG was 12.4 months (range: 1 day to 20.1 months).
Serious adverse reactions occurred in 30% of patients who received WELIREG in combination with pembrolizumab. Serious adverse reactions in ≥1% of patients included pneumonia (2%), hypoxia (1.9%), pneumonitis (1.6%), arrhythmia (1.5%), diarrhea (1.1%), and acute kidney injury (1.1%). Fatal adverse reactions occurred in 1.1% of patients who received WELIREG in combination with pembrolizumab, including sepsis (0.1%).
3 unchanged lines
The most common (≥25%) adverse reactions, including laboratory abnormalities, in patients who received WELIREG in combination with pembrolizumab were decreased hemoglobin, increased ALT, fatigue, increased AST, decreased lymphocytes, and increased alkaline phosphatase.
Tables 56 and 67 summarize the adverse reactions and laboratory abnormalities, respectively, in LITESPARK-022.
Table 56: Adverse Reactions (≥10%) in Patients with ccRCC Who Received WELIREG in Combination with Pembrolizumab [at a Higher Incidence (Between Arm Difference of ≥4%) Compared to Control] in LITESPARK-022
Adverse Reaction | WELIREG plus Pembrolizumab (n=915) | Placebo plus Pembrolizumab (n=913)
11 unchanged lines
Clinically relevant adverse reactions in <10% of patients who received WELIREG in combination with pembrolizumab included hypertension (7%), hypoxia (7%), visual impairment (6.1%), arrhythmia (5%), hemorrhage (4.6%), chest discomfort (2.6%), and palpitations (1.9%).
Table 67: Select Laboratory Abnormalities (>≥20%) That Worsened from Baseline In Patients with ccRCC Who Received WELIREG in Combination With Pembrolizumab [at a Higher Incidence (Between Arm Difference of >≥10%) Compared to Control] in LITESPARK-022
Laboratory Test | WELIREG plus Pembrolizumab | Placebo plus Pembrolizumab
7 unchanged lines
Increased alkaline phosphatase | 29 | 2.3 | 18 | 0.4
LITESPARK-011
The safety of WELIREG in combination with lenvatinib was evaluated in patients with advanced ccRCC that progressed on or after receiving a PD-1 or PD-L1 inhibitor in LITESPARK-011 [see Clinical Studies (14.2)]. Patients received WELIREG 120 mg in combination with lenvatinib 20 mg (n=370), or cabozantinib 60 mg (n=371) orally once daily until disease progression or unacceptable toxicity.
The median duration of exposure to WELIREG was 15.8 months (range: 1 day to 50.6 months).
Serious adverse reactions occurred in 54% of patients who received WELIREG in combination with lenvatinib. Serious adverse reactions in ≥2% of patients included hypoxia (6%), pneumonia (5%), hyponatremia (3.2%), acute kidney injury (3%), hemorrhage (2.7%), anemia (2.7%), cardiac failure (2.4%), and diarrhea (2.4%).
Fatal adverse reactions occurred in 5% of patients who received WELIREG in combination with lenvatinib, including sepsis (0.8%), pneumonia (0.5%), pneumonitis (0.5%), respiratory failure (0.5%), and one case (0.3%) each of acute cholecystitis, acute respiratory distress syndrome, pulmonary edema, embolic cerebral infarction, hemorrhage, postoperative wound complication, thrombotic microangiopathy and upper respiratory tract infection.
Permanent discontinuation of WELIREG due to an adverse reaction occurred in 17% of patients. Adverse reactions which resulted in permanent discontinuation of WELIREG in >0.5% of patients included hypoxia (2.2%), pneumonia (1.1%), fatigue (0.8%), hyponatremia (0.8%), pneumonitis (0.8%), and respiratory failure (0.8%).
Dosage interruptions of WELIREG due to an adverse reaction occurred in 69% of patients. Adverse reactions which required dosage interruption in >3% of patients included fatigue (14%), diarrhea (12%), anemia (9%), vomiting (9%), hypertension (9%), nausea (8%), decreased appetite (5%), abdominal pain (4.6%), COVID-19 (4.6%), musculoskeletal pain (4.1%), pneumonia (3.5%), hypoxia (3.5%), and hemorrhage (3.5%).
Dose reductions of WELIREG due to an adverse reaction occurred in 35% of patients. Adverse reactions which required dose reductions in >2% of patients included fatigue (7%), hypoxia (7%), anemia (6%), diarrhea (3%), and dyspnea (2.4%).
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG in combination with lenvatinib were decreased hemoglobin, fatigue, increased AST, hypertension, increased ALT, musculoskeletal pain, diarrhea, decreased lymphocytes, decreased sodium, increased creatinine, nausea, hypothyroidism, decreased appetite, decreased platelets, increased potassium, increased lipase, proteinuria, decreased magnesium, decreased calcium, increased activated partial thromboplastin time, rash, vomiting, decreased weight, constipation, abdominal pain, and stomatitis.
Tables 8 and 9 summarize the adverse reactions and laboratory abnormalities, respectively, in LITESPARK-011.
Table 8: Adverse Reactions (≥15%) in Patients with Advanced ccRCC Who Received WELIREG in Combination with Lenvatinib in LITESPARK-011
Adverse Reaction | WELIREG plus Lenvatinib (n=370) | Cabozantinib (n=371)
All Grades (%) | Grade 3-4 (%) | All Grades (%) | Grade 3-4 (%)
General
Fatigue | 68 | 16 | 60 | 9
Edema | 17 | 0.3 | 10 | 0.3
Vascular
Hypertension | 60 | 33 | 58 | 30
Hemorrhage | 20 | 3 | 16 | 3
Musculoskeletal and connective tissue
Musculoskeletal pain | 55 | 5 | 43 | 4
Gastrointestinal
Diarrhea | 54 | 8 | 71 | 11
Nausea | 42 | 3.8 | 39 | 1.1
Vomiting | 32 | 0.8 | 17 | 1.1
Constipation | 27 | 0.8 | 23 | 0
Abdominal pain | 26 | 1.6 | 27 | 1.9
Stomatitis | 25 | 1.9 | 46 | 5
Endocrine
Hypothyroidism | 42 | 0.3 | 37 | 0
Metabolism and nutrition
Decreased appetite | 41 | 2.7 | 40 | 3.5
Renal and urinary
Proteinuria | 38 | 10 | 20 | 3.5
Skin and subcutaneous tissue
Rash | 33 | 2.7 | 61 | 10
Investigations
Weight decreased | 29 | 5 | 30 | 6
Nervous system
Headache | 24 | 0.5 | 13 | 0
Dizziness | 16 | 0.8 | 11 | 0.3
Respiratory, Thoracic and Mediastinal
Cough | 19 | 0 | 18 | 0.5
Dyspnea | 17 | 1.9 | 11 | 1.1
Hypoxia | 16 | 12 | 0 | 0
Clinically relevant adverse reactions occurring in <15% of patients who received WELIREG in combination with lenvatinib included COVID-19 (14%), dysphonia (14%), dysgeusia (14%), urinary tract infection (14%), pruritus (12%), pyrexia (11%), and arrhythmia (9%).
Table 9: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline In Patients with Advanced ccRCC Who Received WELIREG in Combination with Lenvatinib in LITESPARK-011
Laboratory Test | WELIREG plus Lenvatinib | Cabozantinib
All Grades % | Grades 3-4 % | All Grades % | Grades 3-4 %
Hematology
Decreased hemoglobin | 87 | 17 | 50 | 7
Decreased lymphocytes | 53 | 15 | 45 | 18
Decreased platelets | 40 | 1.9 | 43 | 0.3
Increased activated partial thromboplastin time | 34 | 2.5 | 27 | 2.5
Decreased neutrophils | 21 | 4.9 | 29 | 3.8
Chemistry
Increased AST | 65 | 7 | 84 | 6
Increased ALT | 56 | 7 | 77 | 7
Decreased sodium | 47 | 7 | 49 | 4.6
Increased creatinine | 42 | 3.8 | 36 | 2.4
Increased potassium | 39 | 5 | 38 | 6
Increased lipase | 38 | 15 | 50 | 17
Decreased magnesium | 37 | 1.4 | 51 | 4.7
Decreased calcium | 35 | 2.4 | 62 | 3.5
Decreased potassium | 23 | 3.5 | 26 | 5
Increased calcium | 20 | 0.3 | 11 | 0.5
LITESPARK-005
The safety of WELIREG was evaluated in a randomized, active-controlled study (LITESPARK- 005) in 732 patients with advanced ccRCC that has progressed after prior PD-1 or PD-L1 checkpoint inhibitor and VEGF receptor targeted therapies [see Clinical Studies (14.2)]. Patients received 120 mg WELIREG (n=372) or 10 mg everolimus (n=360) orally once daily until disease progression or unacceptable toxicity. The median duration of exposure to WELIREG was 7.6 months (range: 0.1 to 28.5 months).
Serious adverse reactions occurred in 38% of patients who received WELIREG. Serious adverse reactions in ≥2% of patients treated with WELIREG were hypoxia (7%), anemia (5%), pneumonia (3.5%), hemorrhage (3%), and pleural effusion (2.2%). Fatal adverse reactions occurred in 3.2% of patients who received WELIREG, including sepsis (0.5%) and hemorrhage (0.5%).
3 unchanged lines
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG were decreased hemoglobin, fatigue, musculoskeletal pain, increased creatinine, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, and increased aspartate aminotransferase.
Table 710 summarizes the adverse reactions in LITESPARK-005.
Table 710: Adverse Reactions (≥10%) in Patients with Advanced RCC Receiving WELIREG in LITESPARK-005
Adverse Reaction | WELIREG (n=372) | Everolimus (n=360)
16 unchanged lines
Decreased Appetite | 13 | 1.1 | 16 | 0
Nervous Systems
Nervous System
Headache | 12 | 0.5 | 8 | 0.3
1 unchanged line
Clinically relevant adverse reactions in <10% of patients who received WELIREG in LITESPARK-005 included hemorrhage (9%) [including intracranial/cerebral hemorrhage (0.8%)], rash (8%), hypertension (6%), visual impairment [including vision blurred (4%), visual acuity decreased (1.1%), visual impairment (0.5%), and retinal detachment (0.3%)] (6%) and increased weight (5%).
Table 811 summarizes the laboratory abnormalities in LITESPARK-005.
Table 811: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline In Patients with Advanced RCC who Received WELIREG in LITESPARK-005
Laboratory Test | WELIREG | Everolimus
20 unchanged lines
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG were anemia, fatigue, musculoskeletal pain, decreased lymphocytes, increased alanine aminotransferase, increased aspartate aminotransferase, increased calcium, dyspnea, increased potassium, decreased leukocytes, headache, increased alkaline phosphatase, dizziness, and nausea.
Table 912 summarizes the adverse reactions reported in patients treated with WELIREG in LITESPARK-015.
Table 912: Adverse Reactions Occurring in ≥10% of Patients with PPGL Who Received WELIREG in LITESPARK-015
Adverse Reaction | WELIREG (n=72)
37 unchanged lines
Palpitations | 10 | 0
Table 1013 summarizes the laboratory abnormalities in LITESPARK-015.
Table 1013: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Patients with PPGL Who Received WELIREG in LITESPARK-015
Laboratory Abnormality | WELIREG (n=72)
15 unchanged lines

Use in specific populations

Changed293 words added, 88 removed
2 unchanged lines
Risk Summary
Refer to the Prescribing Information of the individual therapeutic agents used in combination with WELIREG for pregnancy information.
Based on findings in animal studies, WELIREG can cause fetal harm when administered to a pregnant woman. There are no available data on the use of WELIREG in pregnant women to inform the drug-associated risk. In an animal reproduction study, oral administration of belzutifan to pregnant rats during the period of organogenesis caused embryo-fetal lethality, reduced fetal body weight, and fetal skeletal malformations at maternal exposures ≥0.2 times the human exposure (AUC) at the recommended dose of 120 mg daily (see Data ). Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
5 unchanged lines
Risk Summary
Refer to the Prescribing Information of the individual therapeutic agents used in combination with WELIREG for lactation information. When used in combination, advise patients not to breastfeed during treatment and for the longest post-treatment duration recommended in the Prescribing Information of the individual products.
There are no data on the presence of belzutifan or its metabolites in human milk or their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with WELIREG and for 1 week after the last dose.
8.3 Females and Males of Reproductive Potential
Refer to the Prescribing Information of the individual therapeutic agents used in combination with WELIREG for contraception and infertility information. When used in combination, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of the individual products.
WELIREG can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].
9 unchanged lines
8.4 Pediatric Use
The safety and effectiveness of WELIREG have been established in pediatric patients aged 12 years and older for the treatment of locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma. Use of WELIREG in pediatric patients aged 12 years and older is supported by evidence from an adequate and well-controlled study of WELIREG in adults with additional pharmacokinetic data demonstrating that belzutifan exposure is predicted to be within range of that observed in adults, and that the course of locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma is sufficiently similar in adults and pediatric patients to allow extrapolation of data in adults to pediatric patients [see Clinical Pharmacology (12.3), and Clinical Studies (14.3)].
The safety and effectiveness of WELIREG have not been established in pediatric patients with VHL or ccRCC, or in pediatric patients younger than 12 years of age with PPGL.
8.5 Geriatric Use
Of the 61 patients who received WELIREG for VHL in LITESPARK-004, 3.3% were ≥65 years old [see Clinical Studies (14.1)]. Clinical trials of WELIREG in patients with VHL did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients.
Of the 915 patients who received WELIREG in combination with pembrolizumab for ccRCC in LITESPARK-022, 30% were ≥65 years old and 5% were ≥75 years old [see Clinical Studies (14.2)]. No overall differences in efficacy or safety were reported between patients who were ≥65 years of age and younger patients. Dose interruptions of WELIREG occurred in 57% of patients ≥65 years of age and in 49% of younger patients. Dose reductions of WELIREG occurred in 39% of patients ≥65 years of age and in 32% of younger patients.
Of the 372 patients who received WELIREG for advanced ccRCC in LITESPARK-005, 62% of patients were younger than 65 years, 28% of patients were 65 to 74 years, and 10% were 75 years and over. No overall difference in efficacy was reported between patients who were ≥65 years of age and younger patients. Dose interruptions occurred in 48% of patients ≥65 years of age and in 34% of younger patients. Dose reductions occurred in 18% of patients ≥65 years of age and in 10% of younger patients.
Of the 370 patients who received WELIREG in combination with lenvatinib for advanced ccRCC in LITESPARK-011, 44% of patients were ≥65 years old and 10% were ≥75 years old [see Clinical Studies (14.2)]. Permanent discontinuation, dosage interruption, and dose reductions of WELIREG in patients ≥65 years of old were 23%, 73%, and 42%, respectively, compared with 12%, 65%, and 29%, respectively, in younger patients. No overall differences in effectiveness were reported between patients who were ≥65 years of age and younger patients.
Of the 372 patients who received WELIREG for advanced ccRCC in LITESPARK-005, 62% of patients were younger than 65 years, 28% of patients were 65 to 74 years, and 10% were 75 years and over [see Clinical Studies (14.2)]. No overall difference in efficacy was reported between patients who were ≥65 years of age and younger patients. Dose interruptions occurred in 48% of patients ≥65 years of age and in 34% of younger patients. Dose reductions occurred in 18% of patients ≥65 years of age and in 10% of younger patients.
Of the 72 patients who received WELIREG for PPGL in LITESPARK-015, 13% were ≥65 years old and 4.2% were ≥75 years old [see Clinical Studies (14.3)]. Clinical trials of WELIREG in patients with PPGL did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
6 unchanged lines

Clinical pharmacology

Changedpunctuation or symbols only
14 unchanged lines
Distribution
The estimated mean (CV%) volume of distribution is 119 L (28%). Plasma protein binding of belzutifan is 45%. The blood-to-plasma concentration ratio of belzutifan is 0.88.
Elimination
25 unchanged lines

Nonclinical toxicology

Changed58 words added, 8 removed
1 unchanged line
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity studies have not been conducted with belzutifan.
Carcinogenesis
No carcinogenic risk was identified with belzutifan in a 6-month transgenic rasH2 mouse study with oral administration up to 600 mg/kg/day and a 2-year rat study with oral administration up to 300 mg/kg/day (up to 13 times the human exposure at the recommended dose based on AUC).
Mutagenesis
Belzutifan was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay. Belzutifan was not clastogenic in either an in vitro micronucleus assay or an in vivo rat bone marrow micronucleus assay.
Impairment of Fertility
Fertility studies in animals have not been conducted with belzutifan. In repeat-dose toxicity studies up to 3-month duration, belzutifan-related findings included degeneration/atrophy of testes and hypospermia and cellular debris of the epididymis in rats administered ≥2 mg/kg/day (approximately 0.1 times the human exposure at the recommended dose of 120 mg daily). Findings in testes and epididymis were associated with decreased sperm count and motility and abnormal sperm morphology at ≥6 mg/kg/day (approximately 0.2 times the human exposure at the recommended dose of 120 mg daily) and did not reverse by the end of the recovery period. Belzutifan had no adverse effects on female reproductive organs in repeat-dose toxicity studies up to 3-month duration; however, belzutifan caused embryo-fetal lethality (post-implantation loss) in pregnant rats given oral doses ≥60 mg/kg/day (approximately 1 time the human exposure at the recommended dose based on AUC) during the period of organogenesis [see Use in Specific Populations (8.1)].

Clinical studies

Changed604 words added, 12 removed
2 unchanged lines
The efficacy of WELIREG was evaluated in LITESPARK-004 (NCT03401788), an open-label clinical trial in 61 patients with VHL-associated RCC diagnosed based on a VHL germline alteration and with at least one measurable solid tumor localized to the kidney as defined by response evaluation criteria in solid tumors (RECIST) v1.1. Enrolled patients had other VHL-associated tumors including CNS hemangioblastomas and pNET. CNS hemangioblastomas and pNET in these patients were diagnosed based on the presence of at least one measurable solid tumor in brain/spine or pancreas, respectively, as defined by RECIST v1.1 and identified by IRC. The study excluded patients with metastatic disease. Patients received WELIREG 120 mg orally once daily until disease progression or unacceptable toxicity.
The study population characteristics were: median age 41 years [range: 19-66 years], 3.3% age 65 or older; 53% male; 90% were White, 3.3% were Black or African-American, 1.6% were Asian, and 1.6% were Native Hawaiian or other Pacific Islander; 82% had an ECOG PS of 0, 16% had an ECOG PS of 1, and 1.6% had an ECOG PS of 2; and 84% had VHL Type I Disease. The median diameter of RCC target lesions per central independent review committee (IRC) was 2.2 cm (range: 1-6.1). Median time from initial radiographic diagnosis of VHL-associated RCC tumors that led to enrollment on LITESPARK-004 to the time of treatment with WELIREG was 17.9 months (range: 2.8-96.7). Seventy-seven percent of patients had prior surgical procedures for RCC.
The major efficacy endpoint for the treatment of VHL-associated RCC was objective response rate (ORR) measured by radiology assessment using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 as assessed by IRC. Additional efficacy endpoints included duration of response (DoR), and time to response (TTR).
Table 1114 summarizes the efficacy results for VHL-associated RCC in LITESPARK-004.
Table 1114: Efficacy Results (IRC assessment) for LITESPARK-004 for VHL-Associated RCC
Efficacy Outcome Measure | WELIREG n=61
6 unchanged lines
% (n) with DoR ≥ 12 months | 56% (17/30)
For VHL-associated RCC, median TTR was 8 months (range: 2.7, 19).
Table 1215 summarizes the efficacy results for VHL-associated pNET or CNS hemangioblastomas in LITESPARK-004.
Table 12.15: Efficacy Results (IRC assessment) for LITESPARK-004 for VHL-Associated Subgroups with CNS Hemangioblastomas or pNET
Endpoint | Patients with CNS Hemangioblastomas n=24 | Patients with pNET n=12
6 unchanged lines
% (n) with DoR ≥12 months | 73% (11/15) | 50% (5/10)
For VHL-associated CNS hemangioblastomas, TTR was 3.1 months (range: 2.5, 11). For VHL-associated pNET, median TTR was 8.1 months (range: 2.7, 11).
Decreases in size of CNS hemangioblastoma-associated peri-tumoral cysts and syringes were observed.
3 unchanged lines
Patients were randomized (1:1) to receive WELIREG 120 mg orally once daily in combination with pembrolizumab 400 mg intravenously every 6 weeks (N=921), or oral placebo in combination with pembrolizumab 400 mg intravenously every 6 weeks (N=920) for up to 9 cycles (54 weeks) until disease recurrence or unacceptable toxicity. Randomization was stratified by risk of recurrence (intermediate-high, high risk, M1 NED) and tumor grade (1 or 2 versus 3 or 4).
The study population characteristics were: median age 60 years (range: 20 to 91 years), 32% age 65 or older; 71% male; 63% White; 29% Asian; 3.6% Unknown, 0.7% Black or African American; 1.7% American Indian or Alaska Native, 1.8% Multiracial; 78% Not Hispanic or Latino, 15% Hispanic or Latino, 7% Unknown; 85% ECOG PS 0 and 15% ECOG PS 1. Ninety-six percent of patients enrolled had N0 disease or unknown nodal status; 10% had sarcomatoid features; 85% had intermediate-high risk disease; 6% had high risk disease; and 9% had M1 NED. Ninety percent of patients had a radical nephrectomy, and 10% had a partial nephrectomy.
The major efficacy outcome measure was investigator-assessed disease-free survival (DFS), defined as time to recurrence, metastasis, or death. An additional outcome measure was overall survival (OS). A statistically significant improvement in DFS was demonstrated at pre-specified interim analysis in patients randomized to the WELIREG plus pembrolizumab arm compared with the placebo plus pembrolizumab arm. At the protocol pre-specified interim analysis, OS data were not mature with 29% of the required events for the final analysis.
Table 1316 and Figure 1 summarize the efficacy results for LITESPARK-022.
Table 1316: Efficacy Results for ccRCC for LITESPARK-022
Efficacy Outcome Measure | WELIREG plus Pembrolizumab n=921 | Placebo plus Pembrolizumab n=920
7 unchanged lines
Figure 1: Kaplan-Meier Curve for Disease-Free Survival in LITESPARK-022
In Combination with Lenvatinib for the Treatment of Advanced ccRCC
The efficacy of WELIREG in combination with lenvatinib was evaluated in LITESPARK-011 (NCT04586231), an open-label, randomized, active-controlled clinical trial in 747 patients with advanced ccRCC. Eligible patients had locally advanced or metastatic ccRCC and had progressed on or after a PD-1 or PD-L1 inhibitor, or within 6 months of completing adjuvant therapy with a PD-1 inhibitor. The study excluded patients with hypoxia, active CNS metastases and clinically significant cardiac disease within 6 months before first dose of study intervention.
Patients were randomized in a 1:1 ratio to receive WELIREG 120 mg in combination with lenvatinib 20 mg (n=371), or cabozantinib 60 mg (n=376) orally once daily until disease progression or unacceptable toxicity. Randomization was stratified by IMDC risk categories (favorable versus intermediate versus poor), number of prior lines of therapy (1 versus 2), and geographic region (North America versus Western Europe versus Rest of World). Imaging was performed every 8 weeks for the first 80 weeks, then every 12 weeks thereafter.
The major efficacy endpoints were progression-free survival (PFS) measured by BICR using RECIST v1.1 and overall survival (OS). Additional efficacy endpoints included objective response rate (ORR) by BICR using RECIST v1.1.
The study population characteristics were: median age 63 years (range: 30 to 86 years), 76% male; 87% White; 9% Asian; 1.6% American Indian or Alaska Native; 1.1% multiple races; 0.4% Black or African American; 0.8% not reported; 74% not Hispanic or Latino; 18% Hispanic or Latino; 8% ethnicity not reported. Fifty-eight percent of patients were ECOG performance status 0, 41% were ECOG performance status 1, and 1.2% were ECOG performance status 2. Seventy-two percent of patients had 1 prior line of therapy (4.4% with adjuvant therapy only), 28% had 2 or more prior lines of therapy. Patient distribution by IMDC risk categories was 24% favorable, 59% intermediate, and 17% poor. Bone metastasis was present in 40% of patients; liver metastasis was present in 25%.
The trial demonstrated a statistically significant improvement in PFS and ORR for patients randomized to WELIREG in combination with lenvatinib compared to cabozantinib. The efficacy results for advanced ccRCC in LITESPARK-011 are summarized in Table 17 and Figure 2.
Table 17: Efficacy Results in Patients with Advanced ccRCC in LITESPARK-011
Efficacy Outcome Measure | WELIREG plus Lenvatinib n=371 | Cabozantinib n=376
NS – not statistically significant
Progression-Free Survival (PFS)
Number of events, n (%) | 196 (53%) | 240 (64%)
Progressive disease | 172 (46%) | 211 (56%)
Death | 24 (7%) | 29 (8%)
Median in months (95% CI) | 14.6 (11.1, 16.6) | 10.6 (9.2, 11.1)
Hazard ratio (95% CI) | 0.74 (0.61, 0.89)
p-Value | 0.001
Overall Survival (OS)
Number of events, n (%) | 195 (53%) | 224 (60%)
Median in months (95% CI) | 33.7 (29.0, 46.9) | 28.6 (24.1, 31.4)
Hazard ratio (95% CI) | 0.85 (0.70, 1.03)
p-Value | NS
Confirmed Objective Response Rate
ORR % (n) (95% CI) | 53% (195) (47, 58) | 40% (149) (35, 45)
Complete response | 4% (15) | 1.1% (4)
Partial response | 49% (180) | 39% (145)
p-Value | 0.0002
Among the 195 patients treated with WELIREG in combination with lenvatinib who achieved a confirmed response based on BICR per RECIST 1.1, 122 (63%) patients had a duration of response ≥12 months at the pre-specified final analysis.
Figure 2: Kaplan-Meier Curve for Progression Free Survival in LITESPARK-011
Monotherapy for the Treatment of Advanced ccRCC
1 unchanged line
Patients could have received up to 3 prior treatment regimens and were required to have measurable disease per RECIST v1.1. Patients were randomized in a 1:1 ratio to receive 120 mg WELIREG or 10 mg everolimus orally once daily until disease progression or unacceptable toxicity. Randomization was stratified by IMDC risk categories (favorable versus intermediate versus poor) and number of prior VEGF receptor targeted therapies (1 versus 2-3). Patients were evaluated radiologically at Week 9 from the date of randomization, then every 8 weeks through Week 49, and every 12 weeks thereafter.
The study population characteristics were: median age 63 years [range: 22 to 90 years], 42% age 65 or older; 78% male; 79% White; 12% Asian; 1% Black or African American; 11% Hispanic or Latino; 44% ECOG performance status 0 and 55% ECOG performance status 1. Prior therapies: 13% patients had 1 prior line of therapy, 43% had 2 prior lines of therapy and 43% had 3 prior lines of therapy; 49% received 2 to 3 prior VEGF receptor targeted therapies. Patient distribution by IMDC risk categories was 22% favorable, 66% intermediate, and 12% poor. Common sites of metastasis in patients were 65% lung, 59% lymph nodes, and 49% bone.
The major efficacy endpoints were Progression Free Survival (PFS) measured by BICR using RECIST v1.1 and Overall Survival (OS). Additional efficacy endpoint included objective response rate (ORR) by BICR using RECIST v1.1.
The trial demonstrated a statistically significant improvement in PFS for patients randomized to WELIREG compared with everolimus. Table 1418 and Figure 23 summarize the efficacy results for LITESPARK-005.
Table 1418: Efficacy Results for Advanced ccRCC (IRC assessment) for LITESPARK-005
Efficacy Outcome Measure | WELIREG n=374 | Everolimus n=372
19 unchanged lines
Among the 82 patients treated with WELIREG who achieved a confirmed response based on BICR per RECIST 1.1, 25 (30%) patients had a duration of response ≥12 months.
Figure 23: Kaplan-Meier Curve for Progression-Free Survival in LITESPARK-005
14.3 Pheochromocytoma or Paraganglioma
The efficacy of WELIREG was evaluated in LITESPARK-015 (NCT04924075), an open-label, multi-cohort clinical trial in 72 patients in Cohort A1 who had measurable disease verified by BICR per RECIST v1.1, documented histopathological diagnosis of pheochromocytoma or paraganglioma (PPGL), locally advanced or metastatic disease that was not amenable to surgery or curative treatment, and adequately controlled blood pressure (defined as BP <150/90 mm Hg, <135/85 mm Hg for adolescents) with no change in antihypertensive medications for patients with concomitant hypertension for at least 2 weeks prior to start of study treatment. Patients with carcinomatous meningitis were excluded. Patients received WELIREG 120 mg orally once daily until disease progression or unacceptable toxicity.
The study population characteristics were: median age 52 years [range: 22 to 77 years], 13% age 65 or older; 58% male; 93% White; 4.2% Black or African-American; 1.4% Asian; 6% Hispanic or Latino; 54% had an ECOG PS of 0 and 46% had an ECOG PS of 1. The median number of prior therapies was 1: (range: 0 to 5). A total of 50% of patients received prior chemotherapy, 44% received prior radiopharmaceuticals, and 25% received prior VEGF-TKIs. No patients had a history of VHL disease.
The major efficacy outcome measure for the treatment of locally advanced PPGL was objective response rate (ORR) measured by BICR using RECIST v1.1. Additional efficacy outcome measures were duration of response (DOR), time to response (TTR), and the proportion of patients who had a reduction in at least one antihypertensive medication by at least 50% maintained for at least six months.
Table 1519 summarizes the efficacy results for PPGL in LITESPARK-015.
Table 1519: Efficacy Results in Patients with PPGL in LITESPARK-015
Efficacy Outcome Measure | WELIREG n=72
9 unchanged lines
Proportion of patients (95% CI ) | 32% (20, 45)
For PPGL, the median TTR was 11.0 months (range: 1.7 to 24.8).

Patient counseling information

Changed131 words added, 1 removed
5 unchanged lines
Inform patients that WELIREG can cause severe hypoxia that may require discontinuation, supplemental oxygen, or hospitalization; and that oxygen levels will be monitored routinely during treatment. Advise patients to contact their healthcare provider if the patient experiences any symptoms suggestive of hypoxia [see Warnings and Precautions (5.2)].
Cardiac Dysfunction
Inform patients that WELIREG in combination with lenvatinib can cause cardiac dysfunction. Advise patients to immediately contact their healthcare provider for any symptoms or signs of cardiac dysfunction [see Warnings and Precautions (5.3)].
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.34) and Use in Specific Populations (8.1)].
Advise females of reproductive potential to use effective non-hormonal contraception during treatment with WELIREG and for 1 week after the last dose [see Use in Specific Populations (8.3)].
Advise male patients with female partners of reproductive potential to use effective contraception during treatment with WELIREG and for 1 week after the last dose [see Use in Specific Populations (8.3)].
Refer to the Prescribing Information of the individual therapeutic agents used in combination with WELIREG for pregnancy and contraception information. When used in combination, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of the individual products.
Lactation
Advise females not to breastfeed during treatment with WELIREG and for 1 week after the last dose [see Use in Specific Populations (8.2)].
Refer to the Prescribing Information of the individual therapeutic agents used in combination with WELIREG for lactation information. When used in combination, advise patients not to breastfeed during treatment and for the longest post-treatment duration recommended in the Prescribing Information of the individual products.
Infertility
1 unchanged line
Dosage and Administration
Instruct patients to take their dose of WELIREG at the same time each day (once daily). Advise patients that WELIREG can be taken with or without food. Each tablet should be swallowed whole [see Dosage and Administration (2.1)].

Medication guide

Changed309 words added, 48 removed
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 0609/2026
MEDICATION GUIDE WELIREG® (Well-ih-reg) (belzutifan) tablets
What is the most important information I should know about WELIREG? WELIREG can cause serious side effects, including: Low red blood cell counts (anemia). Low red blood cell counts can be severe. You may need a blood transfusion if your red blood cell counts drop too low. Your healthcare provider will do blood tests to check your red blood cell counts before you start and during treatment with WELIREG. Tell your healthcare provider if you get any symptoms of low red blood cell counts, including tiredness, feeling cold, shortness of breath, chest pain, or fast heartbeat. Low oxygen levels in your body. WELIREG can cause low oxygen levels in your body that can be severe and may require you to stop treatment with WELIREG, receive oxygen therapy, or be hospitalized. Your healthcare provider will monitor your oxygen levels before you start and during treatment with WELIREG. Tell your healthcare provider or get medical help right away if you get symptoms of low oxygen in your body, including shortness of breath or increasedfast heartbeat. Heart problems when WELIREG is taken together with lenvatinib. Serious heart rateproblems, including heart failure, can happen when WELIREG is taken in combination with lenvatinib. Your healthcare provider will check your heart function before and during treatment with WELIREG. Tell your healthcare provider right away if you get symptoms of heart problems, including shortness of breath, swelling of your ankles, unusual weight gain, chest pain, or feeling faint. Harm to your unborn baby. Treatment with WELIREG during pregnancy can cause harm to your unborn baby. Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start treatment with WELIREG. You should useUse an effective form of non-hormonal birth control (contraception) during treatment with WELIREG and for 1 week after your last dose. If you are taking WELIREG in combination with another medicine, your healthcare provider will tell you how long you should use birth control (contraception). Birth control methods that contain hormones (such as birth control pills, injections, or transdermal system patches) may not work as well during treatment with WELIREG. Talk to your healthcare provider about birth control methods that may be right for you during treatment with WELIREG. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with WELIREG. Males with female partners who are able to become pregnant: You should useUse effective birth control (contraception) during treatment with WELIREG and for 1 week after your last dose. Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant whileduring youyour aretreatment takingwith WELIREG. See “What are the possible side effects of WELIREG?” for more information about side effects.
What is WELIREG? WELIREG is a prescription medicine used to treat: von Hippel-Lindau (VHL) disease in adults who need treatment for a type of kidney cancer called renal cell carcinoma (RCC), tumors in the brain and spinal cord called central nervous system (CNS) hemangioblastomas, or a type of pancreatic cancertumor called pancreatic neuroendocrine tumors (pNET), that do not require surgery right away. a type of kidney cancer called renal cell carcinomaRCC with a clear cell component (ccRCC). WELIREG can be used in adults, with the medicine pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, who are at intermediate-high or high risk of kidney cancer coming back after surgery to: remove all or part of the kidney, or remove all or part of the kidney and also surgery to remove cancer that has spread to other parts of the body (metastatic lesions). ccRCCWELIREG incan adultsbe thatused haswith spreadthe (advancedmedicine RCC)lenvatinib following treatment with a programmed death- receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) anti-cancer medicine in adults whose kidney cancer has spread (advanced ccRCC). WELIREG can be used alone following treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) anti-cancer medicines in adults whose kidney cancer has spread (advanced ccRCC). a type of tumor that starts in nerve and hormone making cells (neuroendocrine tumors) called pheochromocytoma or paraganglioma (PPGL) in adults and children 12 years of age and older that have spread to areas near the adrenal glands (locally advanced), or cannot be removed by surgery (unresectable), or that has spread to other parts of the body (metastatic). It is not known if WELIREG is safe and effective in children with VHL or ccRCC, or in children younger than 12 years of age with PPGL.
Before taking WELIREG, tell your healthcare provider about all of your medical conditions, including if you: have low red blood cell counts (anemia) have heart problems (if you will take WELIREG in combination with lenvatinib) are pregnant or plan to become pregnant. See “What is the most important information I should know about WELIREG?” are breastfeeding or plan to breastfeed. It is not known if WELIREG passes into your breast milk. Do not breastfeed during treatment with WELIREG and for 1 week after your last dose. If you are taking WELIREG in combination with another medicine, your healthcare provider will tell you how long you should not breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking WELIREG with certain other medicines canmay affect each otherhow andWELIREG causeor seriousthose sidemedicines effectswork and may affectincrease the way certainrisk otherof medicinesside workeffects. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
How should I take WELIREG? Take WELIREG exactly as your healthcare provider tells you. Do not stop taking WELIREG or change your dose without talking to your healthcare provider. Take your prescribed dose of WELIREG 1 time a day, at the same time each day. Take WELIREG with or without food. Swallow WELIREG tablets whole. Do not chew, crush, or split WELIREG tablets. If you miss a dose of WELIREG, take it as soon as possible on the same day. Then take your next dose of WELIREG at your regular time the next day. Do not take extra tablets to make up for the missed dose. If you vomit after taking a dose of WELIREG, do not take an extra dose. Take your next dose at your regular time the next day. If you take too much WELIREG, call your healthcare provider or go to the nearest emergency room right away.
2 unchanged lines
The most common side effects of WELIREG when taken with pembrolizumab in adults with ccRCC include:
low red blood cell counts increased blood liver enzymes (liver function tests) tiredness | tiredness decreased white blood cell counts
The most common side effects of WELIREG when taken with lenvatinib in adults with advanced ccRCC include:
low red blood cell counts tiredness increased blood liver enzymes (liver function tests) high blood pressure muscle and joint pain diarrhea decreased white blood cell counts decreased blood salts (sodium) levels increased creatinine (kidney function test) nausea decreased levels of thyroid hormone decreased appetite decreased platelet counts | increased blood potassium levels increased blood levels of lipase (a digestive enzyme made by the pancreas) protein in your urine decreased blood magnesium levels decreased blood calcium levels increased blood clotting time rash vomiting weight loss constipation stomach-area (abdomen) pain mouth sores
The most common side effects of WELIREG when taken alone in adults with advanced ccRCC include:
low red blood cell counts tiredness muscle and joint pain increased blood creatinine (kidney function test) | decreased white blood cell counts increased blood liver enzymes (liver function tests) decreased blood salts (sodium) levels increased blood potassium levels
The most common side effects of WELIREG in adults and children 12 years of age and older with PPGL include:
low red blood cell counts tiredness muscle and joint pain decreased white blood cell counts increased blood liver enzymes (liver function tests) increased blood calcium levels | shortness of breath increased blood potassium levels headache dizziness nausea
3 unchanged lines
What are the ingredients in WELIREG? Active ingredient: belzutifan Inactive ingredients: croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, mannitol, microcrystalline cellulose, and silicon dioxide. The film-coating contains FD&C Blue #2 aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
Manufactured for: Merck Sharp & Dohme LLC Rahway, NJ 07065, USA For patent information: www.msd.com/research/patent Copyright © 2021-2026 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. usmg-mk6482-t-2606r0062609r007

Untitled section

Changed1 word added, 2 removed
1 unchanged line
For patent information: www.msd.com/research/patent
Copyright © 2021-2026 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.
uspi-mk6482-t-2606r0052609r006

Unchanged: Dosage forms and strengths, Contraindications, Drug interactions, Overdosage, Description, How supplied/storage and handling, PRINCIPAL DISPLAY PANEL - 40 mg Bottle Label.

Every version

9 versions of set 13e15ee0-d679-4fa9-9430-e2e2170474da, newest first.
VersionPublished on DailyMedCompareSPL file
13Oct 12, 2026Shown belowDownload .zip
12Jun 29, 2026With version 11Download .zip
11May 23, 2025With version 10Download .zip
10Apr 30, 2025With version 7Download .zip
7Jan 24, 2024With version 6Download .zip
6Jan 8, 2024With version 5Download .zip
5Nov 20, 2023With version 3Download .zip
3Jun 14, 2022With version 2Download .zip
2Aug 24, 2021First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.